Xoma/Ingene merger
Executive Summary
There is "absolutely no reason whatsoever that [Ingene's previous R&D agreement with NeoRx] will create any complication" in the proposed merger with Xoma, an Ingene spokesperson said in response to a story on the merger in the Aug. 14 issue of "The Pink Sheet" (T&G-1). "There is no expectation that any of Ingene's previous arrangements will cause any difficulty with the merger," Xoma said. "The Pink Sheet" had stated that Ingene's arrangement with NeoRx "complicates" the merger. According to Ingene, the NeoRx deal announced in April 1988 gives NeoRx "exclusive worldwide rights to products which contain the chimeric antibodies developed from NeoRx's mouse monoclonals".
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.